T he loss of expression of the cyclin-dependent kinase (Cdk ) inhibitor, p16 INK4a , occurs in the overwhelming majority of mesothelioma cell lines and tumors examined. 1 As seen in a variety of other tumors, the molecular phenotype of absence of p16
INK4a expression is associated with retention of wild -type expression of the critical cell cycle regulator pRB. Re -expression of p16
INK4a in mesothelioma cells and xenografts is associated with cell cycle arrest, cell growth inhibition, and apoptosis. 2 Mesothelioma presents clinically with tumors involving the parietal or visceral pleura or, less commonly, the parietal peritoneum. 3 Because of the anatomical location of these cancers within a body cavity, these tumors have presented attractive targets for intracavitary gene therapy. Currently, gene therapy approaches using direct instillation of viral vectors into the pleural cavity in mesothelioma are being carried out. 4 The present study was designed to treat, prolong survival, and cure mice with established mesothelioma xenografts with p16
INK4a -based gene therapy, and compare these therapies directly to no treatment or treatment with gene therapy expressing only a control protein, -galactosidase.
MATERIALS AND METHODS

Cell lines and cell culture
The cell lines used in this study were derived, characterized, and propagated as previously published. 4 ± 7 Mesothelioma cell lines were obtained in collaboration with Dr. Frederick Kaye (National Cancer Institute ). All the studies used cells propagated in RPMI 1640 media supplemented with 10% fetal bovine serum. Four mesothelioma cell lines that had previously been shown to be sensitive to Adp16 transduction in vitro were tested in the murine model. 2 The mesothelioma cell lines H513, H2373, H2461, and H2595 grow as adherent cultures in standard tissue culture dishes. All mesothelioma cell lines we previously examined have shown cell growth inhibition when transduced with the Adp16 vector.
2 Like all mesothelioma cell lines that have been examined, these four cell lines retain wild -type expression of pRB while demonstrating no expression of the p16
INK4a gene product, thus possessing a molecular phenotype that should be sensitive to p16
INK4a -mediated cell cycle inhibition. 2 
Adenoviral vectors
Construction, propagation, and titering of the Adp16 and Adlacz viral vectors are described elsewhere. 8 Viral stocks ( both p16
INK4a ± and -galactosidase ±expressing vectors) were propagated in 293 cells from a single plaque and were subsequently tested for gene product expression by immunoblotting as described.
2 Viral stocks were then titered and frozen in glycerol aliquots for use in the study. Prior to freezing, stocks were tested on the control cell lines (cell lines to be treated in experiments described ) to ensure that they remained replication -deficient. The Adp16 construct expresses a functional p16
INK4a that is translated from a start codon eight codons past the consensus start codon as first reported. 9 The resulting protein is slightly smaller than the endogenous p16 INK4a protein, yet remains fully functional in its capacity to inhibit Cdk4-mediated phosphorylation and to suppress cell growth. 2, 7, 8, 10, 11 The Adp16 vector was generated at the Gene Therapy Program, University of Alabama, Birmingham. 8 
Intraperitoneal tumors
In experiments in which established tumors were treated, athymic nude mice (Balb /C ) (Harlan, Indianapolis, IN ) were inoculated with 1Â10 7 mesothelioma cells 1, 2, or 4 weeks prior to beginning treatment with the viral vectors. Although the animals developed widespread diffuse intraperitoneal disease, mice with established mesothelioma xenografts that died usually developed progressive obstructive jaundice as previously described from common bile duct involvement with tumor. 12 
Adenoviral injections
Adenoviral injections were carried out in a volume of 100 L of sterile phosphate -buffered saline injected directly into the intraperitoneal cavity. Injections consisted of 1Â10 9 pfu /injection for both vectors. 12 The titer used in these injections was the minimum previously demonstrated to result in gene product expression in murine mesothelioma intraperitoneal xenografts. 13 Injections began after a fixed period for the development of intraperitoneal tumors, which varied depending upon the growth rate of the tumors derived from the various cell lines ( Fig 1) . Once treatments started, injections were delivered three times a week for the remainder of the animal's life. Animals that appeared premorbid from their disease were euthanized. For cell line H2373, one experiment began after 2 weeks of tumor growth, and the second after 4 weeks. However, in experiments involving the more rapidly growing cell line H513, one experiment began after 1 week of tumor growth, and the second after 2 weeks. Attempts to grow H513 tumors for 4 weeks resulted in the death of the animals before the end of the 4 weeks of tumor growth from progressive disease prior to beginning the treatments. Injections of the mesothelioma cell line, H2461, began after 4 weeks of tumor growth. In all of the experiments, four groups of five mice were tested. This number, although small, would provide sufficient power to demonstrate a 5-fold increase in survival (P=.05 ). One group consisted of untreated mice that were sacrificed at the time that treatment began in order to assure the development of widespread intraperitoneal disease, a second group received no treatment, a third group received Adlacz, and the final group received Adp16 (Fig 1 ) .
Statistical analysis
Survival curves were calculated by the Kaplan -Meier method and compared using the log rank test, with a P value of < .05 considered significant. Calculations were performed using SPSS 1 for Windows (release 6.1, Chicago, IL ) .
RESULTS
Three of four cell lines that had previously demonstrated sensitivity to in vitro transduction of the p16
INK4a gene 2 were found to be capable of forming intraperitoneal tumors and were subsequently tested in our murine xenograft model. A fourth cell line, H2595, which had been tested in previous in vitro studies, failed to form tumors after injection into mice in our model system and thus could not be used in these studies. Tumors that arose following intraperitoneal injection of 1Â10 7 cells of the H2373 cell line were allowed to grow for either 2 (Fig 2 ) or 4 weeks ( Fig 3 ) following implantation. Following the 2-or 4-week period of tumor establishment and growth, mice were started on treatment with either Adp16, Adlacz, or no treatment. There were five mice in each of the three arms of the study. A fourth group of mice was sacrificed at the time of the beginning of therapy (2 or 4 weeks after implantation) to assure establishment of intraperitoneal disease. In all cases when this control group was sacrificed at the time of commencing treatment, there was diffuse disease throughout the peritoneal cavity of the mice. In the two arms of the studies that received adenoviral treatment ( Adp16 or Adlacz ), viral therapies were intraperitoneally delivered at a dosage of 10 9 pfu every Monday, Wednesday, or Friday (Fig 1 ) . In both of these experiments, there were mice alive exclusively in the Adp16 treatment group at the time when all of the mice in the other two arms were dead ( Figs 2 and 3 ) . In the experimental cohort that began treatment following 2 weeks of tumor growth (Fig 2) , Kaplan -Meier survival analysis demonstrated a strong statistical significance in improved survival in the Adp16-treated group as compared to the untreated or Adlacz -treated mice ( P= .0309 ). The treatment group that started treatment after 4 weeks of tumor growth appeared to have superior survival in the Adp16-treated group as well ( Fig 3) , although it did not reach statistical significance. At the time that all of the mice in the untreated or Adlacz -treated groups were dead of progressive disease (as identified at necropsy) , two mice remained alive in the Adp16 -treated group. One of these was a long -term survivor and following sacrifice was found to be free of disease and likely cured.
Mice that received the H513 cell line had a more aggressive disease course ( consistent with the more robust in vitro growth of this cell line ) and thus were treated beginning only 1 and 2 weeks following tumor establishment ( Fig 1 ) . Mice that had treatment, which began 1 week after tumor establishment, had an apparent trend toward superior survival in the Adp16 -treated group (P=.0725 ) ( Fig 4 ) , although eventually all mice died of progressive disease. All of these treatment groups possessed subcutaneous (extraperitoneal ) tumors that grew at the cell injection site. These extraperitoneal tumors grew and progressed equally in all arms of the study, suggesting the absence of any detectable antitumor effect outside of the peritoneum from intraperitoneally administered Adp16 therapy. In mice with tumor xenografts from H513 cells that were allowed to grow for 2 weeks prior to beginning treatment, there was a less pronounced trend toward superior survival ( P= .1311) (Fig 5) . However, as in the previous experiments, the mice surviving the longest were from the Adp16-treated group.
Mice receiving a third cell line, H2461, in addition to developing extensive intraperitoneal disease, developed sanguinous (bloody ) peritoneal effusions. This was different from the previous two cell lines tested. Following 4 weeks of tumor growth after implantation, the mice were treated as in the previous experiments. This time, however, there was no difference in survival between any of the treatment or control groups ( P= .9528 ) ( Fig 6 ) .
In summary, a total of 75 mice with well -established and diffusely spread intraperitoneal mesothelioma xenografts were treated with Adp16 therapy (n =25) , Adlacz (n =25), or no treatment (n = 25) . Three different cell lines were used and several different time points for beginning treatment were tested. In general, Adp16 treatment was associated with a longer survival in all but the H2461 cell line. When the five experiments were analyzed as an aggregate (Fig 7) , Adp16 therapy was associated with a highly significant prolongation ( P= .0050 ) in survival when compared to the other two modalities (Fig 7 ) . There was no significant difference in survival in any of the trials between the no treatment and Adlacz treatment groups. The one mesothelioma cell line in which there was no therapeutic effect was the H2461 cell line, which produced sanguinous effusions in all mice injected with this cell line (including the group receiving no treatment) . Excluding this cell line from the aggregate analysis demonstrated an even stronger significance ( P= .0010 ) toward the beneficial effects of Adp16 therapy.
DISCUSSION
Mesothelioma is a largely incurable cancer of the pleural or peritoneal linings of the body cavities. 3, 14 It progresses locally with metastases occurring in only the latest stages of disease. As such, it makes an attractive theoretical target for locally administered gene -based therapies. 4 Loss of p16
INK4a gene product expression is perhaps the most common molecular abnormality in these tumors. In this study, we have identified that re -expression of exogenous p16
INK4a by adenoviral -based vectors appears to be effective in the murine model for prolonging life and possibly curing this disease in some cases. As our protocol was designed to study intraperitoneal tumors in the absence of whole body scanning, we cannot adequately address whether Adp16 therapy results only in slower tumor progression or in tumor regression followed by progression. It is a compelling evidence of tumor regression; however, it should be noted that the few long -surviving mice were all in the Adp16-treated groups, including mice with no detectable disease. Our previous studies demonstrated that re -expression of p16
INK4a results in apoptosis of mesothelioma cells, which would be consistent with a model of tumor regression. 2 In any event, it is obvious that as currently designed, the effectiveness of this therapy appears modest in its potential to cure these mesothelioma xenografts. In comparison, the effects seen in the current study appear less dramatic than those previously described for mesothelioma xenografts using virally transduced HSVtk followed by ganciclovir. 15 One of the major drawbacks with the technology we have used is the need for high levels of vector administration. The doses we gave, 10 9 pfu three times per week, were largely limited by the amount of vector that we could conveniently produce and deliver. It is likely that higher doses of vector would result in increasingly greater therapeutic effect consistent with the previously demonstrated in vitro dose response data. 2 One of the cell lines tested, H2461, was totally resistant in the murine model to Adp16 therapy. This cell line has been shown to be sensitive to in vitro transduction of Adp16. 2 This highlights another potential deficiency in adenoviralbased therapy. Although these therapies can be effectively delivered in humans and are currently in clinical trials, 4 these vectors are quickly inactivated in blood. It is possible that sanguinous (bloody ) effusions may prove refractory to this type of therapy. Many of the pleural effusions that are observed in mesothelioma are found to be sanguinous. 
